Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?

Focal therapy for localized prostate cancer has sparked debate among medical professionals, with new research potentially shifting opinions. A recent U.K. study revealed that 10 years post-treatment, just 0.1% of patients undergoing focal therapy had died from prostate cancer, matching survival rates achieved through conventional treatments such as surgery or radiation. This finding has energized advocates of focal therapy, who argue that the approach offers superior quality of life due to fewer side effects, including reduced risks of incontinence and erectile dysfunction. However, critics remain cautious, calling for more rigorous clinical trials to confirm the method's efficacy against established standards. The controversy stems from the fundamental differences between focal therapy and traditional approaches. For most localized solid tumors, surgeons aim to remove only the affected area while preserving the rest of the organ, minimizing damage. In contrast, prostate cancer treatment often follows an all-or-nothing model, with the entire gland typically removed or subjected to radiation unless the cancer is deemed low-risk. This binary approach can lead to significant long-term complications, prompting some patients and doctors to seek alternatives. Focal therapy, which emerged as a less invasive option, focuses on targeting specific cancerous areas identified via advanced MRI imaging. It employs techniques such as cryotherapy, laser ablation, and high-intensity focused ultrasound (HIFU) to eliminate cancer cells without affecting surrounding healthy tissue. These procedures are generally outpatient, reducing recovery time and hospital stays. Despite being available since the late 1990s, the technique gained traction as MRI technology improved, allowing for more accurate lesion detection. At recent urology conferences, focal therapy was a prominent discussion point, highlighting both its promise and unresolved questions. Medical experts remain divided on focal therapy’s role in standard practice. While some urologic oncologists support its use, particularly for intermediate-risk cases, others insist on more robust evidence before endorsing it widely. The American Urological Association classifies focal therapy as experimental, recommending it only within clinical trials or registries. A recent analysis found that nearly half of patients receiving focal therapy had cancers classified as either higher or lower risk, raising concerns about whether the treatment is appropriately matched to individual patient profiles. Despite these reservations, many leading cancer centers and independent practitioners continue to offer focal therapy, drawing patients seeking alternatives to conventional treatments. Patient testimonials reflect high satisfaction, although financial barriers persist. Chris Brosseau, a 48-year-old from Denver with a family history of aggressive prostate cancer, opted for focal therapy instead of active surveillance, radiation, or surgery. His out-of-pocket cost was approximately $17,000, as most commercial insurance plans do not cover the procedure, though Medicare does. Brosseau expressed confidence in his decision, noting he experiences no side effects and would consider repeating the treatment if necessary. The landscape of focal therapy includes a range of FDA-approved technologies, each suited to different tumor characteristics. Cryotherapy, once the dominant method, saw a decline in usage from nearly 80% of procedures in 2010 to 20% by 2023. Laser ablation, used in about 45% of cases, involves directing a focused beam to destroy targeted cells. High-intensity focused ultrasound (HIFU), which utilizes high-frequency sound waves to generate heat and kill cancer cells, is rapidly becoming the preferred choice, accounting for 35% of procedures in 2023. As these technologies evolve, so too does the potential for focal therapy to reshape the treatment paradigm for prostate cancer.